Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, parallel-group, dose finding study to assess the efficacy and safety of ZD6474 in patients with advanced, metastatic, or recurrent NSCLC who have failed previous chemotherapy regimens, at least one of which contained platinum

Trial Profile

A randomised, double-blind, parallel-group, dose finding study to assess the efficacy and safety of ZD6474 in patients with advanced, metastatic, or recurrent NSCLC who have failed previous chemotherapy regimens, at least one of which contained platinum

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2008 Results published in the Journal of Clinical Oncology, April, 2008.
    • 28 Jun 2007 Status changed from in progress to completed.
    • 22 Dec 2005 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top